Dehydroevodiamine is an alkaloid that has been isolated from E. rutaecarpa and has anti-inflammatory, antiarrhythmic, hypotensive, and anti-amnesic biological activities.1,2,3,4 It inhibits LPS-induced secretion of prostaglandin E2 in RAW 264.7 mouse macrophages when used at a concentration of 30 μM.1 Dehydroevodiamine (0.1-0.3 μM) reduces the upstroke velocity, action potential amplitude, and contractile force of electrically-stimulated primary human atrial trabeculae.2 In vivo, dehydroevodiamine (10 mg/kg) decreases mean arterial blood pressure (MAP) by approximately 30% in rats.3 Dehydroevodiamine (1.5 mg/kg) also inhibits amnesia induced by amyloid-β (25-35) and increases latency to step-through in a passive avoidance test in mice.4
1.Noh, E.J., Ahn, K.S., Shin, E.M., et al.Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-κB activation in RAW 264.7 macrophagesLife Sci.79(7)695-701(2006) 2.Loh, S.-H., Tsai, Y.-T., Lee, C.-Y., et al.Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytesJ. Ethnopharmacol.153(3)753-762(2014) 3.Yang, M.C.M., Wu, S.-L., Kuo, J.-S., et al.The hypotensive and negative chronotropic effects of dehydroevodiamineEur. J. Pharmacol.182(3)537-542(1990) 4.Wang, H.-H., Chou, C.-J., Liao, J.-F., et al.Dehydroevodiamine attenuates β-amyloid peptide-induced amnesia in miceEur. J. Pharmacol.413(2-3)221-225(2001)